Shots:
- The P-III CLEAR study involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg, IV, q3w) or in combination with everolimus (5mg, qd) vs sunitinib (50 mg, q4w) in 1,069 patients for the 1L treatment with advanced RCC
- The trial met its 1EPs with Keytruda + Lenvima shows 61% reduction in the risk of disease progression or death, mPFS (2yrs. vs 9 mos.) 2 EPs shows 34% reduced the risk of death, ORR (71.0% vs 36.1%); CR (16.1 vs 4.2%); PR( 54.9% vs 31.9%); mDoR(25.8 vs 14.6mos)
- Lenvima + everolimus shows 35% reduction in the risk of disease progression or death; mPFS (14.7 vs 9.2mos); CR (9.8% vs 4.2%); PR (43.7% vs 36.1%); mDOR (16.6 vs 14.6 mos.)@median follow-up 27 mos.
Click here to read full press release/ article | Ref: Merck | Image: The New York Times
The post Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma first appeared on PharmaShots.
